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Abstract
Introduction: Renin-angiotensin system (RAS) inhibitors have been postulated to influence susceptibility to Severe
Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). This study investigated whether there is an association
between their prescription and the incidence of COVID-19 and all-cause mortality.
Methods: We conducted a propensity-score matched cohort study comparing the incidence of COVID-19 among
patients with hypertension prescribed angiotensin-converting enzyme I (ACE) inhibitors or angiotensin II type-1
receptor blockers (ARBs) to those treated with calcium channel blockers (CCBs) in a large UK-based primary care
database (The Health Improvement Network). We estimated crude incidence rates for confirmed/suspected COVID-
19 in each drug exposure group. We used Cox proportional hazards models to produce adjusted hazard ratios for
COVID-19. We assessed all-cause mortality as a secondary outcome.
Results: The incidence rate of COVID-19 among users of ACE inhibitors and CCBs was 9.3 per 1000 person-years (83 of
18,895 users [0.44%]) and 9.5 per 1000 person-years (85 of 18,895 [0.45%]), respectively. The adjusted hazard ratio was
0.92 (95% CI 0.68 to 1.26). The incidence rate among users of ARBs was 15.8 per 1000 person-years (79 out of 10,623
users [0.74%]). The adjusted hazard ratio was 1.38 (95% CI 0.98 to 1.95). There were no significant associations between
use of RAS inhibitors and all-cause mortality.
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Conclusion: Use of ACE inhibitors was not associated with the risk of COVID-19 whereas use of ARBs was associated
with a statistically non-significant increase compared to the use of CCBs. However, no significant associations were
observed between prescription of either ACE inhibitors or ARBs and all-cause mortality.
Background
A novel strain of coronavirus, Severe Acute Respiratory
Syndrome Coronavirus-2 (SARS-CoV-2), was first de-
tected in December 2019 in the district of Wuhan,
China. This infection was found to cause a severe re-
spiratory illness, termed COVID-19, which was associ-
ated with the development of acute respiratory distress
syndrome (ARDS), particularly in older male adults, in
those with obesity and comorbidities, and those from
Black and Minority Ethnic backgrounds and low socio-
economic status [1]. The virus has caused a global pan-
demic that has crippled health systems and economies.
As of 3rd January 2021, SARS-CoV-2 was estimated to
have infected over 100 million people and caused over
2.2 million deaths [2].
Early on in the pandemic, a number of case series of
patients with COVID-19 in China indicated a high
prevalence of hypertension among those affected [3, 4].
Patients with hypertension appeared to have a threefold
increase in the odds of mortality from COVID-19 com-
pared to those without [5]. It is unclear whether this as-
sociation was causal, and if so whether hypertension or
antihypertensive drugs increased the risk of adverse out-
comes from COVID-19. The renin angiotensin system
(RAS) inhibitors, angiotensin-converting enzyme I
(ACE) inhibitors and angiotensin II type-1 receptor
blockers (ARBs), were specifically postulated to be in-
volved in the pathogenesis of SARS-CoV-2 [6].
SARS-CoV-2 enters human cells using the angiotensin-
converting enzyme 2 (ACE2) receptor, which is expressed
in epithelial cells in human organs, including type II alveo-
lar cells in the lungs as well as the cardiovascular system,
kidneys, adrenal glands, brain, uterus and skin [7–9]. Ex-
perimental studies have suggested that use of ACE inhibi-
tors and ARBs can upregulate ACE2 receptor expression
in the cardiovascular and renal system [10]. Furthermore,
the pathways within the renin-angiotensin system are
complex and ACE inhibitors and ARBs may theoretically
be protective because they increase concentrations of
ACE2 and angiotensin [1–7], which have been shown to
be protective in lung injury models [11].
The relationship between ACE inhibitors and ARBs
and risk of COVID-19 need to be clarified as a large pro-
portion of patients with hypertension, type 2 diabetes,
heart failure, and chronic kidney disease, all of which are
considered risk factors for COVID-19, are currently pre-
scribed these drugs. In the absence of this evidence, it
would not be appropriate to withdraw or switch these
drugs as they are known to be cardioprotective and
renoprotective. The Council on Hypertension of the
European Society of Cardiology highlighted the lack of
evidence supporting harmful effects of ACE inhibitors
and ARBs in the context of COVID-19 early on in the
pandemic [12]. Pharmacoepidemiological studies which
account for confounding by indication bias are needed
to address this evidence gap [13, 14].
Several epidemiological studies have attempted to in-
vestigate the association between RAS inhibitors and
COVID-19 susceptibility. Some of the earliest published
case-control studies, in Lombardy, Italy [15] and
Denmark, found no significant association between use
of RAS inhibitors and COVID-19 susceptibility, severity
or mortality [16]. However, these studies included pa-
tients with a range of conditions that could also be indi-
cations for RAS inhibitors, introducing the potential for
confounding by indication bias.
The ideal study design to answer this question would
be a randomised controlled trial comparing RAS inhibi-
tors to comparator drugs. However, such a trial would
likely be unfeasible given the widespread use of these
drugs in everyday clinical practice. However, one ap-
proach to disentangling the independent relationship be-
tween COVID-19 susceptibility and exposure to RAS-
inhibitors is to study patients with hypertension while
excluding those with other indicator conditions such as
cardiovascular or chronic kidney disease, and comparing
the incidence of COVID-19 among similar patients who
have received a RAS inhibitor to those who have re-
ceived an active comparator drug such as a calcium
channel blocker (CCB). The objective of this study is to
assess whether there is an independent association be-
tween the use of RAS-inhibitors and incidence of




This is a propensity score-matched cohort study with ac-
tive comparators, using routine primary care data.
Data source
We used data from The Health Improvement Network
database. This is a large database of primary care records
from UK general practices that use Vision electronic
health record software. It includes data for approximately
14 million patients (2 million active patients) at over 640
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primary care practices. It includes coded data on patient
demographics, diagnoses, primary care prescriptions, con-
sultations and investigations. Practices contributing data
to primary care as of 30th Jan 2020 (index date) were eli-
gible for inclusion if they had shown acceptable mortality
reporting and had the Vision system installed on or before
30th Jan 2019. Investigators had direct access to an up-to-
date extract of the data source.
Study population
Adults aged 18 years and older with a diagnosis of
hypertension and who were registered with an eligible
general practice before 30th Jan 2019 were included. In
our primary analysis, we excluded patients with heart
failure, diabetes, cardiovascular disease (ischaemic heart
disease, transient ischaemic attack, stroke, and periph-
eral vascular disease), and chronic kidney disease (in-
cluding patients with an estimated glomerular filtration
rate < 30/min/1.73m2) as these comorbidities repre-
sented alternative indications for RAS inhibitors. We
also excluded all patients who were pregnant during the
index date or had contraindications to the exposure
drugs (e.g. hypersensitivity to ACE inhibitors).
Exposed and comparator groups
We derived three main cohorts of patients defined by
their prescription of one of three antihypertensive drugs
- angiotensin-converting enzyme inhibitors (ACE inhibi-
tors) and angiotensin II receptor blockers (ARBs), which
were the two exposure drugs of interest, and calcium
channel blockers (CCBs), which was the active compara-
tor. Drug prescriptions were ascertained using recorded
British National Formulary (BNF) codes.
In the primary analysis, all three cohorts were mutu-
ally exclusive and patients having a concurrent prescrip-
tion of any two of the three medications were excluded.
To avoid any residual effect of any of the other two
medications in their respective cohorts, those with a pre-
ceding prescription of any of the other two medications
after 30th October 2019 (3 month washout period) were
excluded. However, patients were still included if they
had a concurrent prescription of other antihypertensive
classes (e.g. diuretics and beta-blockers), but these vari-
ables were used to propensity score match the exposure
and comparator cohort and further adjusted for in the
outcome analysis.
Matching
We estimated propensity scores for prescription of the
treatment of interest (ACE inhibitor/ARB) using logistic
regression, including the covariates listed below. Matched
paired exposure groups (ACE inhibitors vs CCBs and
ARBs vs CCBs) were created after performing 1:1 propen-
sity score matching using the nearest-neighbour
algorithm, considering calipers of width equal to 0.2. We
matched without replacement. We assessed the covariate
balance of the matched groups by calculating the stan-
dardized absolute mean difference (SMD), considering
SMD below 0.10 a balanced covariate.
Outcomes
The primary outcome was a composite of confirmed or
suspected diagnosis of COVID-19 recorded using the
clinical (Read) codes recommended in national guide-
lines (clinical codes are listed in Supplementary Table 1)
[17]. Confirmed SARS-CoV-2 infection was defined by a
positive reverse transcriptase polymerase chain reaction
(RT-PCR) swab result. Clinicians entered a suspected
SARS-CoV-2 infection code when there was no RT-PCR
testing available in the presence of either a compatible
clinical picture, confirmation with other investigations
(e.g. imaging) or contact with a confirmed case. A recent
study on suspected COVID-19 codes recorded in pri-
mary care suggested that clinical diagnosis of COVID-19
by physicians followed a similar trend to test positive
cases confirmed by the UK national testing service [18].
We also assessed all-cause mortality as a secondary
outcome. A negative control was used to assess for re-
sidual confounding [19]. This was a composite of acci-
dents, trauma or fractures, which was chosen on the
basis that we did not expect it to be differentially associ-
ated with either the drugs of interest or the outcome.
Follow-up period
Patients were followed up from the 30th January 2020
until the earliest of the following: recording of the out-
come (as defined above), death, patient left practice/
dataset, practice ceased contributing to the database,
and study end (22nd July 2020). The latest available
baseline covariate data recorded before 30th January
2020 were obtained. We retrospectively captured out-
come records available until the study end date.
Covariates
Baseline covariates were extracted for propensity score
matching and model adjustment, which included:
1) Sociodemographic characteristics - age and sex.
2) Lifestyle risk factors and metabolic profile: smoking
status, alcohol consumption, body mass index
(BMI), blood pressure, total cholesterol, high
density lipoprotein (HDL), and estimated
glomerular filtration rate (eGFR).
3) Duration of hypertension and age of hypertension
diagnosis.
4) Presence of comorbid conditions including those
listed as high risk for COVID-19 [12, 13]: chronic
respiratory disease (including severe asthma and
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COPD), atrial fibrillation, rheumatoid arthritis, can-
cers (excluding skin cancer), haematological condi-
tions (including haematological malignancies) and
immunosuppressive conditions (including immuno-
deficiency, use of immunosuppressive drugs,
chemotherapy and radiotherapy, antibody treatment
for cancer, and solid organ transplant).
5) Concurrent prescriptions for thiazide diuretics,
potassium diuretics, alpha-adrenoceptor blockers,
beta-adrenoceptor blockers, other antihypertensives,
statins, and anticoagulants, as defined based on
BNF chapters.
Sample size
The study sample size was not determined by an a priori
sample size calculation. Rather, we included all patients
meeting the study eligibility criteria. There have already
been over 300,000 confirmed COVID-19 diagnoses re-
corded in the UK general population. Considering the
prevalence of hypertension to be 30% [20], and the
THIN database constituting more than 2 million active
patients, we expected to have sufficient power to detect
differences in the incidence rates of the primary out-
come. We included all current users of the exposure
drugs as described in the section above, minimizing se-
lection bias by using the maximum sample size available.
Statistical analysis
We used basic descriptive statistics to summarize the
characteristics of the patients in each of the prescription
cohorts before and after propensity score matching.
Crude incidence rates of each outcome were calculated
with 95% confidence intervals (CIs). In the primary ana-
lysis, we applied a Cox proportional hazards regression
model to determine crude and adjusted hazard ratios
(HR) comparing pairs of treatment groups in patients
with hypertension. The models were adjusted for the co-
variates listed above. The Cox proportional hazards as-
sumption was tested using Schoenfeld’s residuals test
and log-log plots. P-values below 0.05 were considered
statistically significant.
Sensitivity analyses
We repeated the primary analyses comparing outcomes
for patients who used ACE inhibitors with or without
CCBs to those prescribed CCBs without a RAS inhibitor.
We did the same with patients prescribed ARBs with or
without a CCB to those prescribed a CCB. This enabled
the sample size to be increased while still assessing the
additional effect of the exposure drug over and above
the active comparator.
The primary analysis was also repeated including pa-
tients with diabetes mellitus, ischemic heart disease,
stroke or TIA and peripheral vascular disease, mirroring
the inclusion criteria used by Fosbøl et al. [16]. We also
repeated the analysis further including patients with
hypertension, CKD and heart failure, as was done in the
study by Mancia et al. [15, 19–21]. This allowed us to
assess the potential effect of confounding by indication
bias introduced by including patients with different indi-
cations for the exposure drugs.
Missing data
Continuous variables such as age, BMI, and total choles-
terol were grouped into clinically meaningfully categor-
ies. Missing values for smoking status and other
categorical variables were treated as a separate missing
categorical variable. The absence of a record of any diag-
nosis (e.g. hypertension, renal disease) was taken to indi-
cate the absence of these conditions.
Ethical approval
The THIN data collection scheme and research carried
out using THIN data were approved by the NHS South-
East Multicentre Research Ethic Committee in 2003.
Under the terms of the approval, studies must undergo
independent scientific review. Approval for this study
was obtained from the THIN Scientific Review Commit-
tee in June 2020 (SRC protocol reference 20–003-R2).
Results
Population selection
Before matching, there were 31,194 individuals with a
prescription for ACE inhibitors, 13,377 with a prescrip-
tion for ARBs, and 27,500 with a prescription for CCBs
at the index date. After matching, there were 18,895 pa-
tients in each arm of the ACE inhibitor and CCB paired
cohorts and 10,623 in each arm of the ARB and CCB
paired cohorts (Fig. 1). The median follow-up was 0.48
(interquartile range 0.48 to 0.48) years.
Study participants
ACE inhibitors versus calcium channel blockers
Before matching, the mean age of users of ACE inhibi-
tors and CCBs was 60.8 years and 67.4, respectively
(Table 1). The proportion that were male was slightly
higher for users of ACE inhibitors than users of CCBs
(48.8% vs 45.6%, respectively). A similar proportion were
current smokers but a greater proportion of users of
ACE inhibitors were overweight or obese compared to
users of CCBs (77.7% vs 69.1%, respectively).
Duration of hypertension was slightly longer for users
of ACE inhibitors than CCBs (9.8 years vs 8.6 years, re-
spectively). Systolic and diastolic blood pressure (BP),
cholesterol, and renal function were similar across both
groups. The prevalence of comorbidities was also similar
between groups, except for cancers and respiratory
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disease, which were slightly more common in the CCB
cohort.
21.9% of the CCB cohort had previously used an
ACE inhibitor and 26.4% of the ACE inhibitor co-
hort had previously used a CCB. Prescription of
other antihypertensives was similar between groups
except for thiazide diuretics, which was slightly more
common in the ACE inhibitor cohort (18.5% in users
of ACE inhibitors vs 14.3% in users of CCBs). Pre-
scriptions of statins were also similar between both
cohorts.
Following propensity score matching, users of ACE
inhibitors and CCBs were similar in age (64.7 years vs
63.4 years, respectively). Other characteristics were
well balanced, including demographic, behavioural
and metabolic risk factors, comorbidities and pre-
scriptions (Table 1).
Angiotensin II receptor blockers versus calcium channel
blockers
Before matching, the mean age of users of ARBs was
younger than users of CCBs [63.8 years vs 67.4, respect-
ively (Table 1)]. However, the proportion of males was
slightly lower in users of ARBs than CCBs (40.2% vs
45.6%, respectively). A smaller proportion of users of
ARBs were current smokers compared to users of CCBs
(7.9% vs 12.7%, respectively). A greater proportion of
users of ARBs were overweight or obese than users of
CCBs (79.1% vs 69.1%).
The ARB cohort had a longer mean duration of hyper-
tension than the CCB cohort (11.4 years vs 8.6, respect-
ively) and a younger mean age at hypertension diagnosis
(52.4 years vs 58.8). BP, cholesterol and renal function
were similar between groups, as was the prevalence of
comorbidities.
Fig. 1 Number of subjects at each stage of the study
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Table 1 Baseline characteristics of the primary analysis cohorts




















Age, mean (SD) 60.8 (11.7) 67.4 (10.8) 64.7 (11.2) 63.4 (9.6) 63.8 (11.3) 67.4 (10.8) 65.0 (11.1) 64.55 (11.5)
Age categories, n (%)
18–30 years 123 (0.4) 28 (0.1) 34 (0.2) 28 (0.2) 23 (0.2) 28 (0.1) 14 (0.1) 26 (0.2)
30–40 years 875 (2.8) 309 (1.1) 213 (1.1) 308 (1.6) 206 (1.5) 309 (1.1) 118 (1.1) 238 (2.2)
40–50 years 4466 (14.3) 1302 (4.7) 1445 (7.7) 1297 (6.9) 1298 (9.7) 1302 (4.7) 834 (7.9) 865 (8.1)
50–60 years 10,214 (32.7) 4836 (17.6) 5018 (26. 6) 4694 (24.8) 3556 (26.6) 4836 (17.6) 2623 (24.7) 2472 (23.3)
60–70 years 8448 (27.1) 9521 (34.6) 5879 (31. 1) 7969 (42.2) 4157 (31.1) 9521 (34.6) 3388 (31.9) 3497 (32.9)
70–80 years 5380 (17.3) 8376 (30.5) 4666 (24.7) 3974 (21.0) 3097 (23.2) 8376 (30.5) 2703 (25.4) 2617 (24.6)
> 80 years 1688 (5.4) 3128 (11.4) 1640 (8.7) 625 (3.3) 1040 (7.8) 3128 (11.4) 943 (8.9) 908 (8.6)
Sex (Male), n (%) 15,213 (48.8) 12,547 (45.6) 8870 (46.9) 9243 (48.9) 5379 (40.2) 12,547 (45.6) 4628 (43.6) 4463 (42.0)
Smoker categories, n (%)
Non Smoker 17,968 (57.6) 15,514 (56.4) 10,725 (56.8) 10,668 (56.5) 8390 (62.7) 15,514 (56.4) 6384 (60.1) 6473 (60.9)
Ex-Smoker 9073 (29.1) 8329 (30.3) 5677 (30.0) 5700 (30.2) 3865 (28.9) 8329 (30.3) 3186 (30.0) 3137 (29.5)
Smoker 3962 (12.7) 3483 (12.7) 2402 (12.7) 2431 (12.9) 1058 (7.9) 3483 (12.7) 1005 (9.5) 967 (9.1)
Missing 191 (0.6) 174 (0.6) 91 (0.5) 96 (0.5) 64 (0.5) 174 (0.6) 48 (0.5) 46 (0.4)
Drinker Categories, n (%)
Non-drinker 4716 (15.1) 4186 (15.2) 2874 (15.2) 2856 (15.1) 2013 (15.1) 4186 (15.2) 1587 (14.9) 1508 (14.2)
Drinker without excess 11,716 (37.6) 10,281 (37.4) 7082 (37.5) 7134 (37.8) 5157 (38.6) 10,281 (37.4) 4023 (37.9) 3976 (37.4)
Excessive Drinker 7614 (24.4) 6238 (22.7) 4464 (23.6) 4673 (24.7) 2908 (21.7) 6238 (22.7) 2414 (22.7) 2368 (22.3)
Missing 7148 (22.9) 6795 (24.7) 4475 (23.7) 4232 (22.4) 3299 (24.7) 6795 (24.7) 2599 (24.5) 2771 (26.1)
BMI, mean (SD) 30.3 (6.4) 28.44 (5.6) 29.36 (6.0) 29.48 (5.7) 30.37 (6.2) 28.44 (5.6) 29.58 (5.9) 29.65 (5.9)
BMI Categories, n (%)
Underweight (< 18.5) 173 (0.6) 343 (1.3) 151 (0.8) 105 (0. 6) 67 (0.5) 343 (1.3) 65 (0.6) 62 (0.6)
Underweight (< 25) 5597 (17.9) 6898 (25.1) 4059 (21.5) 3645 (19.3) 2243 (16.8) 6898 (25.1) 2074 (19.5) 2033 (19.1)
Overweight (25–30) 10,948 (35.1) 10,536 (38.3) 7156 (37.9) 7171 (38.0) 4718 (35.3) 10,536 (38.3) 4055 (38.2) 3894 (36.7)
Obese (> 30) 13,300 (42.6) 8470 (30.8) 6771 (35.8) 7271 (38.5) 5854 (43.8) 8470 (30.8) 4004 (37.7) 4185 (39.4)
Missing 1176 (3.8) 1253 (4.6) 758 (4.0) 703 (3.7) 495 (3.7) 1253 (4.6) 425 (4.0) 449 (4.2)
Hypertension duration, mean years
(SD)
9.8 (7.4) 8.6 (7.5) 9.4 (6.9) 9.4 (8.0) 11.4 (7.5) 8.6 (7.5) 10.5 (7.0) 11.3 (8.3)
Age at hypertension diagnosis,
mean (SD)
51.0 (10.9) 58.8 (11.2) 55.3 (10.4) 54.0 (9.1) 52.4 (10.9) 58.8 (11.2) 54.5 (10.4) 53.2 (11.0)
Systolic BP, mean (SD) 135.9 (13.8) 137.3 (13.6) 136.7 (14.0) 136.4 (13.1) 136.3 (13.6) 137.3 (13.6) 136.8 (13.6) 136.6 (13.4)
Diastolic BP, mean (SD) 81.7 (9.4) 79.76 (9.3) 80.6 (9.3) 81.09 (9.0) 80.8 (9.1) 79.8 (9.3) 80.5 (9.2) 80.5 (9.3)
Missing, n (%) 80 (0.3) 63 (0.2) 0 (0%) 0 (0%) 22 (0.2) 63 (0.2) 0 (0%) 0 (0%)
Cholesterol, mean (SD) 5.13 (1.03) 5.13 (1.04) 5.12 (1.04) 5.13 (1.04) 5.13 (1.01) 5.13 (1.04) 5.14 (1.02) 5.13 (1.03)
Cholesterol Categories, n (%)
< 5.2 mmol/L 17,051 (54.7) 14,915 (54.2) 10,430 (55.2) 10,394 (55.0) 7415 (55.4) 14,915 (54.2) 5820 (54.8) 5894 (55.5)
5.2–6.2 mmol/L 8852 (28.4) 7712 (28.0) 5262 (27.9) 5323 (28.2) 3836 (28.7) 7712 (28.0) 3026 (28.5) 2929 (27.6)
> = 6.2 mmol/L 4153 (13.3) 3747 (13.6) 2543 (13.5) 2580 (13.7) 1699 (12.7) 3747 (13.6) 1419 (13.4) 1404 (13.2)
Missing 1138 (3.7) 1126 (4.1) 660 (3.5) 598 (3.2) 427 (3.2) 1126 (4.1) 358 (3.4) 396 (3.7)
HDL, mean (SD) 1.44 (0.43) 1.54 (0.46) 1.49 (0.44) 1.48 (0.44) 1.48 (0.43) 1.54 (0.46) 1.50 (0.44) 1.50 (0.45)
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63.0% of users of ARBs had previously used an ACE in-
hibitor, compared to 21.9% of users of CCBs. 40.3% of the
ARB cohort had previously used a CCB while 6.9% of the
CCB cohort had previously used an ARB. Users of ARBs
were more likely than users of CCBs to have been pre-
scribed thiazide diuretics as well as other antihypertensive
drugs. However, the proportion with a prescription for
statins was slightly greater in the CCB cohort.
Following propensity score matching, characteristics
were well balanced between both groups, including
demographic characteristics, behavioural risk factors,
metabolic profile, comorbidities, and prescriptions
(Table 1).
Outcomes
ACE inhibitors versus calcium channel blockers
Before matching, 148 individuals (0.47%) in the ACE inhibi-
tor cohort developed suspected or confirmed COVID-19
during 14,733 person-years of follow-up, representing a
crude incidence rate of 10.1 per 1000 person-years
(Table 2). One hundred twenty-six individuals (0.46%) in
the CCB cohort developed suspected or confirmed
COVID-19 during 12,985 person-years, representing a
crude incidence rate of 9.70 per 1000 person-years in the
CCB cohort. The unadjusted hazard ratio for suspected/
confirmed COVID-19 comparing the ACE inhibitor cohort
to the CCB cohort (as the reference) was 1.04 (95% CI 0.82
Table 1 Baseline characteristics of the primary analysis cohorts (Continued)




















HDL categories, n (%)
< 1.55 mmol/L 19,720 (63.2) 14,873 (54.1) 10,949 (58.0) 11,464 (60.
7)
8160 (61.0) 14,873 (54.1) 6214 (58.5) 6251 (58.8)
> = 1.55 mmol/L 9851 (31.6) 11,114 (40.4) 7007 (37.1) 6566 (34.8) 4621 (34.5) 11,114 (40.4) 3915 (36.9) 3818 (35.9)
Missing 1623 (5.20) 1513 (5.5) 939 (5.0) 865 (4.6) 596 (4.5) 1513 (5.5) 494 (4.7) 554 (5.2)
eGFR, mean (SD) 86.1 (14.7) 82.8 (13.8) 83.33 (14.3) 85.08 (14.0) 82.9 (14.6) 82.8 (13.8) 82.36 (14.2) 83.89 (14.7)
eGFR category, n (%)
> 60 (Stage 2 and above) 29,735 (95.3) 25,680 (93.4) 17,806 (94.2) 17,924 (94.9) 12,538 (93.7) 25,680 (93.4) 9981 (94.0) 9927 (93.5)
30–59(Stage 3) 1127 (3.6) 1270 (4.6) 847 (4.5) 792 (4.2) 713 (5.3) 1270 (4.6) 530 (5.0) 578 (5.4)
Missing 332 (1.1) 550 (2.0) 242 (1.3) 179 (1.0) 126 (0.9) 550 (2.0) 112 (1.1) 118 (1.1)
Baseline conditions, n (%)
Atrial fibrillation 726 (2.3) 743 (2.7) 503 (2.7) 502 (2.7) 384 (2.9) 743 (2.7) 318 (3.0) 332 (3.1)
Rheumatoid arthritis 460 (1.5) 497 (1.8) 329 (1.7) 297 (1.6) 199 (1.5) 497 (1.8) 161 (1.5) 166 (1. 6)
Cancer 2525 (8.1) 3320 (12.1) 1921 (10.2) 1711 (9.1) 1377 (10.3) 3320 (12.1) 1151 (10.8) 1139 (10.7)
Respiratory Disease 1325 (4.3) 1695 (6.2) 1010 (5.4) 933 (4.9) 664 (5.0) 1695 (6.2) 586 (5.5) 572 (5.4)
Immunosuppresseda 571 (1.8) 616 (2.2) 392 (2.1) 358 (1.9) 239 (1.8) 616 (2.2) 205 (1.9) 198 (1.9)
Rare metabolic disorder 29 (0.1) 38 (0.1) 23 (0.1) 18 (0.1) 18 (0.1) 38 (0.1) 15 (0.1) 13 (0.1)
Other medications at baseline, n (%)
Previous prescription of ACE-I 31,194 (100) 6030 (21.9) 18,895 (100) 4462 (23.6) 8421 (63.0) 6030 (21.9) 5686 (53.5) 5638 (53.1)
Previous prescription of ARB 1036 (3.3) 1907 (6.9) 937 (5.0) 762 (4.0) 13,377 (100) 1907 (6.9) 10,623 (100) 1492 (14.0)
Previous prescription of CCB 8242 (26.4) 27,500 (100) 5554 (29.4) 18,895 (100) 5393 (40.3) 27,500 (100) 4001 (37.7) 10,623 (100)
Thiazide diuretics 5775 (18.5) 3919 (14.3) 5775 (18.5) 3919 (14.3) 3457 (25.8) 3919 (14.3) 2074 (19.5) 2468 (23.2)
Loop diuretics 768 (2.5) 461 (1.7) 768 (2.5) 461 (1.7) 417 (3.1) 461 (1.7) 331 (3.1) 219 (2.1)
Potassium diuretics 148 (0.5) 101 (0.4) 148 (0.5) 101 (0.4) 85 (0.6) 101 (0.4) 59 (0.6) 69 (0.7)
Alpha blockers 1017 (3.3) 659 (2.4) 1017 (3.3) 659 (2.4) 661 (4.9) 659 (2.4) 430 (4.1) 481 (4.5)
Beta blockers 3525 (11.3) 3030 (11.0) 3525 (11.3) 3030 (11.0) 1630 (12.2) 3030 (11.0) 1302 (12.3) 1423 (13.4)
Other antihypertensive 122 (0.4) 84 (0.3) 122 (0.4) 84 (0.3) 71 (0.5) 84 (0.3) 48 (0. 5) 48 (0.5)
Anticoagulants 884 (2.8) 889 (3.2) 884 (2.8) 889 (3.2) 446 (3.3) 889 (3.2) 370 (3.5) 385 (3.6)
Statins 9399 (30.1) 9133 (33.2) 9399 (30.1) 9133 (33.2) 3977 (29.7) 9133 (33.2) 3293 (31.0) 3230 (30.4)
a(Treatment with immunosuppressive therapies/antibody treatment/solid organ transplant/ chemo/radiotherapies)
ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, CCB calcium channel blocker
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to 1.31), which fell slightly to 1.01 (95% 0.78 to 1.30) after
adjusting for measured confounders.
Following propensity score matching, 83 individuals
(0.44%) in the ACE inhibitor cohort had suspected or
diagnosed COVID-19 during 8923 person-years of
follow-up, representing a crude incidence rate of 9.30
per 1000 person-years. Eighty five individuals (0.45%)
in the CCB cohort developed suspected or confirmed
COVID-19 during 8932 person-years of follow-up
representing a crude incidence rate of 9.5 per 1000
person-years. The unadjusted hazard ratio for sus-
pected/confirmed COVID-19 comparing the ACE in-
hibitor cohort to the CCB cohort was 0.98 (95% CI
0.72 to 1.32). Upon adjustment for measured con-
founders, the hazard ratio was 0.92 (95% 0.68 to 1.26;
Fig. 2).
Similar results were found in the sensitivity ana-
lyses for the primary outcome. When comparing
hypertensive users of ACE inhibitors with or without
CCBs to those using CCBs alone, the adjusted haz-
ard ratio was 0.95 (95% CI 0.72 to 1.25) following
propensity score matching. When including individ-
uals with diabetes mellitus, ischemic heart disease,
stroke, transient ischaemic attack and peripheral vas-
cular disease, the adjusted hazard ratio for COVID-
19 after propensity score matching was 0.91 (95% CI
0.74 to 1.12). When including individuals with any
comorbidities, the adjusted hazard ratio after pro-
pensity score matching was similarly 0.98 (95% CI
0.81 to 1.18; Fig. 3).
The propensity score-matched analysis for all-cause
mortality produced a statistically non-significant ad-
justed hazard ratio of 1.25 (95% CI 0.90 to 1.73). The
negative control analysis similarly found no statisti-
cally significant association between prescription of
ACE inhibitors and accidents, trauma or fractures
compared to prescription of CCBs (adjusted HR 0.95,
95% CI 0.77 to 1.17).
Fig. 2 Forest plot of adjusted hazard ratios for suspected or confirmed COVID-19, all-cause mortality and accidents, trauma and fractures (negative control)
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Angiotensin II receptor blockers versus calcium channel
blockers
Before matching, 99 individuals (0.74%) in the ARB co-
hort developed suspected or confirmed COVID-19 over
a follow-up of 6308 person-years, representing a crude
incidence rate of 15.7 per 1000 person-years. 126
(0.46%) in the CCB cohort developed suspected or con-
firmed COVID-19 over a follow-up of 12,985 person-
years, representing a crude incidence rate of 9.7 per
1000 person-years. The unadjusted hazard ratio for sus-
pected or confirmed COVID-19 when comparing the
ARB cohort to the CCB cohort (as the reference) was
1.62 (95% CI 1.24 to 2.10). After adjustment for mea-
sured confounders, the hazard ratio was slightly attenu-
ated to 1.51 (95% CI 1.12 to 2.03), although it remained
statistically significant.
After propensity score matching, 79 individuals
(0.74%) in the ARB cohort developed suspected or con-
firmed COVID-19 over 5010 person-years of follow-up,
representing a crude incidence rate of 15.8 per 1000
person-years. In the CCB cohort, 58 individuals (0.55%)
developed suspected or confirmed COVID-19 over 5016
years of follow-up, representing a crude incidence rate
of 11.6 per 1000 person-years. The unadjusted hazard
ratio when comparing the ARB cohort to the CCB co-
hort was 1.36 (95% CI 0.97 to 1.91). After adjustment
for measured confounders, the hazard ratio increased
slightly to 1.38 (95% CI 0.98 to 1.95; Fig. 2).
These findings were attenuated in sensitivity analyses
when comparing users of ARBs with or without concur-
rent use of CCBs to propensity score-matched individ-
uals using CCBs alone (adjusted HR 1.18, 95% CI 0.86 to
1.61). When only excluding individuals with either heart
failure or CKD, the adjusted hazard ratio was slightly at-
tenuated compared to the primary analysis but statisti-
cally significant after propensity score matching
(adjusted HR 1.28, 95% CI 1.00 to 1.63). This was
similarly found when including propensity score-
matched individuals with any comorbidity (adjusted HR
1.24, 95% CI 1.00 to 1.54; Fig. 3).
There was no statistically significant difference in all-
cause mortality between users of ARBs compared to
users of CCBs after propensity score matching (adjusted
HR 0.85, 95% CI 0.56 to 1.30). Similarly, there was no
association between use of ARBs and the negative con-
trol outcome of accidents, trauma and fractures when
compared to propensity score matched users of CCBs
(adjusted HR 0.97, 95% CI 0.74 to 1.27).
Discussion
Main findings
We found no difference in the risk of developing sus-
pected or confirmed COVID-19 or all-cause mortality
among individuals with hypertension treated with ACE
inhibitors compared to those treated with CCBs, after
matching and adjusting for a wide range of risk factors
known to be associated with COVID-19, as well as indi-
cations for ACE inhibitor prescription. We found a 38%
relative increase in the risk of the development of sus-
pected or confirmed COVID-19 among those prescribed
ARBs compared to those prescribed CCBs that did not
reach statistical significance in the propensity score
matched analysis. We also found no difference in all-
cause mortality.
Relationship to other studies
There has been ongoing debate over whether RAS inhib-
itors are protective or harmful in the context of COVID-
19. Concerns were raised early on in the pandemic
speculating that this class of drugs could increase sus-
ceptibility to COVID-19 by upregulating ACE2 recep-
tors, and thus promoting entry of SARS-CoV-2 virus
into host cells [21]. Two in vivo studies in rats showed
that ACE inhibitors increased ACE2 activity in the
Fig. 3 Forest plot of hazard ratios for suspected or confirmed COVID-19 when including comorbidities that were excluded in the primary analysis
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plasma and renal cortex [22, 23]. However, these studies
involved far higher doses of ACE inhibitors than would
typically be used in humans. In fact, a review of 11 hu-
man studies overwhelmingly showed that RAS inhibitors
do not increase plasma or urine ACE2 expression, al-
though it remains unknown whether there is any effect
on membrane-bound ACE2 activity; indeed, there are no
studies to date on the effects of RAS inhibitors specific-
ally on lung ACE2 expression [10, 24].
Once within the cell, coronaviruses themselves down-
regulate ACE2 expression in host cells, which is under-
stood to reduce the pulmonary activity of the anti-
inflammatory ACE2/angiotensin 1–7/mas receptor sys-
tem [7, 21]. This results in angiotensin II proliferation
and consequent lung inflammation. In one small study
of hospitalised patients with COVID-19, angiotensin II
levels were markedly elevated and linearly associated
with viral load and severity of lung injury [25]. Both
ACE inhibitors and ARBs have been shown to attenuate
the inflammatory response in mouse models, potentially
through the inhibition of interleukin 6 (IL-6) [26].
It is possible that RAS inhibitors confer a protective
effect through their anti-inflammatory actions, although
further evidence of such a mechanism is needed. Two
small case series in humans both found that SARS-CoV-
2 infected patients on RAS inhibitors had significantly
lower inflammatory markers, and increased CD3 and
CD8 T cell proliferation than patients on alternative an-
tihypertensive medications [7, 27, 28].
More recently, meta-analyses of observational studies
have also shown that RAS inhibitors are not associated
with severe outcomes and death in hospitalised patients
with COVID-19. In a pooled analysis of 16 studies, RAS
inhibitor use was non-significantly associated with lower
odds of developing severe disease (OR 0.81, 95% CI 0.41
to 1.58) and mortality (OR 0.86, 95% CI 0.53 to 1.41)
[29]. Similarly, in a pooled analysis of 11 studies, Pranata
et al. found a non-significantly lower adjusted odds of
mortality in those on RAS inhibitors (OR 0.83, 95% CI
0.54 to 1.27) but no difference for disease severity (OR
1.03, 95% CI 0.73 to 1.45) [30]. In contrast to our find-
ings, a subgroup analysis found that ARBs were associ-
ated with reduced mortality (OR 0.51, 95% CI 0.29 to
0.90) but the association was not statistically significant
for ACE inhibitors (OR 0.68, 95% CI 0.39 to 1.17).
A meta-analysis of five observational studies also
showed a reduced risk of critical or fatal outcomes
among patients with COVID-19 who took RAS inhibi-
tors, with a pooled odds ratio of 0.32 (95% CI 0.22 to
0.46) [31]. Ghosal et al. similarly showed a reduction in
the odds of severe disease and death (OR 0.56 for severe
illness, 95% CI 0.34 to 1.89, and OR 0.38 for death, 95%
CI 0.19 to 0.74) [32]. A systematic review of RAS inhibi-
tors and COVID-19 by Zhang et al. also showed that
their use was not associated with increased likelihood of
testing positive for SARS-CoV-2 or with severity of dis-
ease once infected [33].
The studies included in these meta-analyses were
largely based on hospital cohorts, in contrast to our
study which included patients registered in primary
care. Prescriptions of and compliance with pre-
hospital medications may be much better recorded in
primary care cohorts. Hospital-based cohorts typically
include the most severely ill patients and do not in-
clude those with asymptomatic or mild-to-moderate
disease. Furthermore, many of the included studies
did not adjust effect estimates for potential confound-
ing factors or assess the effects of sub-classes of RAS
inhibitors (ACE inhibitors and ARBs) separately,
which our study suggests may not be uniform.
Mancia et al. conducted a large population-based
study in Lombardy of those diagnosed with COVID-19
matched to population controls on age, sex and geog-
raphy [15]. After multivariable adjustment, neither ACE
inhibitors nor ARBs showed an association with the risk
of developing COVID-19 (OR 0.95 [95% CI 0.86 to 1.05]
and 0.96 [95% CI 0.87 to 1.07], respectively. Another
large retrospective cohort and nested case-control study
of all Danish people assessed in hospital with COVID-19
in a 3 month period found no association between ACE
inhibitor/ARB use and susceptibility to COVID-19 or
mortality when compared with other antihypertensives
[16].
A large multinational cohort study, which used pro-
pensity score matching and negative controls found, as
we did, that prescription of ACE inhibitors or ARBs was
not associated with the risk of diagnosis of COVID-19 in
comparison to use of calcium channel blockers or thia-
zide diuretics [34]. When directly comparing invididuals
prescribed ACE inhibitors with those prescribed ARBs,
there was a higher risk of COVID-19 diagnosis in the
latter. However, there were no significant differences in
COVID-19 related hospitalisation between all antihyper-
tensive drug classes.
Most recently, a prospective cohort study using data
from general practices in England found that use of ACE
inhibitors or ARBs was associated with a significantly re-
duced risk of COVID-19 but not associated ICU admis-
sion [35]. This study also found that ethnicity modified
the association between use of RAS inhibitors and
COVID-19, with those from Black ethnic groups being
at increased risk, a trend we were not able to explore in
our study.
The above studies included patients with a range of
comorbidities that were potential indications for RAS
inhibitors and were therefore potentially prone to pre-
scription by indication bias. We limited our inclusion
criteria to patients with hypertension and excluded
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those with other conditions that were potential indi-
cations for RAS inhibitors in our main analysis to
limit the effect of these biases. However, our findings
remained largely in line with these prior studies.
Strengths and limitations
The primary outcome of suspected or confirmed
COVID-19 may not have been well recorded in pri-
mary care records. The current cumulative incidence
of COVID-19 in the UK is 5.6%, whereas the inci-
dence in our cohorts ranged from 0.44 to 0.74%.
Relatively little testing for COVID-19 occurred early
in the pandemic and data flows from COVID-19 test-
ing centres and hospitals to primary care has gener-
ally been suboptimal. However, we expect this effect
to have been equally distributed across all our in-
cluded drug exposure cohorts and it should therefore
not have biased our effect estimates. Furthermore, the
higher cumulative incidence of COVID-19 currently
reported in the UK also includes asymptomatic cases
derived from increased community testing that had
not been occurring earlier on in the pandemic in the
period when our cohorts were derived.
We did not have access to data on hospitalisations or
cause-specific mortality. Because of the low numbers of
deaths in each drug exposure cohort, we did not have
sufficient statistical power to assess the association be-
tween drug exposures and COVID-19 mortality. We also
had insufficient data on ethnicity and socioeconomic sta-
tus to include this in our analyses, both of which are
known to be associated with COVID-19.
The strengths of the study include the study design,
which attempted to control for confounding by indica-
tion bias and adjust for a large number of known risk
factors for COVID-19. We also performed multiple sen-
sitivity analyses to check the robustness of our findings
in comparison with other published studies.
Implications for practice, policy and research
Despite initial concerns about the safety of ACE inhibi-
tors in the context of SARS-CoV-2 pathophysiology,
they appear to have no effect on susceptibility to
COVID-19 compared to the use of CCBs. Our findings
should provide further reassurance, in addition to previ-
ously published studies on this topic, that prescription of
ACE inhibitors does not increase vulnerability to being
infected with SARS-CoV-2.
However, our findings suggest that the effects of
RAS inhibitors are not uniform across drug classes.
ARBs by contrast were associated with a statistically
non-significant increased risk of presentation with
COVID-19, but not mortality, in comparison to the
use of CCBs. The reasons for this are unclear but
one potential reason may be due to differential
health-seeking behaviour between users of ACE inhib-
itors and ARBs. One common side effect of ACE in-
hibitors is cough due to the reduced breakdown of
bradykinin and substance P, which are degraded by
ACE, and a rise in prostaglandins due to increased
concentrations of bradykinin [36]. Patients who ex-
perience cough secondary to ACE inhibitors are fre-
quently switched to ARBs, and indeed a large
proportion of patients in our ARB cohort had been
previously prescribed an ACE inhibitor. Those pre-
scribed ARBs could therefore be more prone to
coughing, which could, in turn, have made them
more likely to present to healthcare services with
symptoms of COVID-19. Reassuringly, we did not see
any association between use of ARBs and all-cause
mortality during the peak of the pandemic, supporting
the hypothesis that the association between their use
and COVID-19 is likely related to differences in
health seeking behaviour rather than a true increase
in susceptibility to the infection.
An alternative hypothesis is that the differences in
COVID-19 risk observed between ACE inhibitors and
ARBs is due to residual confounding. We did not for ex-
ample have data on ethnicity or socioeconomic status
and it is possible that patients from different ethnic
groups or social classes could be prescribed antihyper-
tensives differentially and have different patterns of
health-seeking behaviour.
Nevertheless, there remains the possibility that the
higher risk of COVID-19 observed among users of ARBs
is causal and that this class of drugs increases suscepti-
bility to SARS-CoV-2 but not all-cause mortality. Fur-
ther research is needed to test the biological plausibility
and causality of this apparent effect. Further research is
also needed to assess whether the use of ACE inhibitors
and ARBs is associated with COVID-19 hospitalisation
and death and whether any such associations differ be-
tween drug classes.
Conclusions
Prescription of ACE inhibitors was not associated with
the risk of suspected or confirmed COVID-19 in primary
care. By contrast, prescription of angiotensin II receptor
blockers was associated with a statistically non-
significant increase in risk. However, neither drug class
was associated with all-cause mortality during the
first peak of the pandemic. These findings need to be
confirmed in other observational studies, potential path-
ways modelled through causal inference studies, and the
basic mechanistic science of this potential association to
be understood before recommendations can be made on
the clinical implications for RAS inhibitor use during the
ongoing COVID-19 pandemic.
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